Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance?
作者信息
Haricharan Svasti, Ellis Matthew J
机构信息
Lester and Sue Smith Breast Center, Baylor College of Medicine, Houston, TX 77030, USA.
出版信息
Oncoscience. 2017 Sep 21;4(7-8):77-78. doi: 10.18632/oncoscience.363. eCollection 2017 Jul.
Abstract
摘要
相似文献
1
Defects in mismatch repair: the Achilles heel of estrogen receptor positive breast cancer with intrinsic endocrine therapy resistance?错配修复缺陷：雌激素受体阳性且具有内在内分泌治疗耐药性的乳腺癌的致命弱点？
Oncoscience. 2017 Sep 21;4(7-8):77-78. doi: 10.18632/oncoscience.363. eCollection 2017 Jul.
2
Notch Signaling Pathway and Endocrine Resistance in Breast Cancer.Notch信号通路与乳腺癌的内分泌耐药性
Front Pharmacol. 2020 Jun 19;11:924. doi: 10.3389/fphar.2020.00924. eCollection 2020.
3
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.MutL 缺失通过 CDK4/6 破坏 CHK2 依赖性细胞周期控制，从而促进原发性乳腺癌的内在内分泌治疗耐药性。
Cancer Discov. 2017 Oct;7(10):1168-1183. doi: 10.1158/2159-8290.CD-16-1179. Epub 2017 Aug 11.
4
Molecular Mechanisms of Endocrine Resistance in Estrogen-Positive Breast Cancer.雌激素阳性乳腺癌内分泌耐药的分子机制。
Front Endocrinol (Lausanne). 2021 Mar 25;12:599586. doi: 10.3389/fendo.2021.599586. eCollection 2021.
5
Molecular Action and Clinical Relevance of Aromatase Inhibitors.芳香化酶抑制剂的分子作用及临床相关性
Oncologist. 1998;3(2):129-130.
6
The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.激素敏感型晚期乳腺癌患者内分泌治疗类型与雌激素受体 1 突变发展的相关性：一项随机和非随机试验的系统评价和荟萃分析。
Biochim Biophys Acta Rev Cancer. 2019 Dec;1872(2):188315. doi: 10.1016/j.bbcan.2019.188315. Epub 2019 Oct 21.
7
Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers.全面分析乳腺癌的 DNA 修复缺陷，鉴定出一类新型的内分泌治疗抵抗驱动因素。
Clin Cancer Res. 2018 Oct 1;24(19):4887-4899. doi: 10.1158/1078-0432.CCR-17-3702. Epub 2018 May 23.
8
Molecular signatures of neoadjuvant endocrine therapy for breast cancer: characteristics of response or intrinsic resistance.乳腺癌新辅助内分泌治疗的分子特征：反应或内在抗性的特点
Breast Cancer Res Treat. 2008 Dec;112(3):475-88. doi: 10.1007/s10549-008-9897-4. Epub 2008 Mar 9.
9
Endocrine therapy in post-menopausal women with metastatic breast cancer: From literature and guidelines to clinical practice.绝经后转移性乳腺癌患者的内分泌治疗：从文献和指南到临床实践。
Crit Rev Oncol Hematol. 2016 Apr;100:57-68. doi: 10.1016/j.critrevonc.2016.02.008. Epub 2016 Feb 18.
10
A modified perforator-based stepladder V-Y advancement flap in the Achilles tendon area for coverage of larger posterior heel defects.基于改良穿支皮瓣的梯式 V-Y 推进皮瓣在跟腱区的应用，用于覆盖更大的后部足跟缺损。
J Plast Reconstr Aesthet Surg. 2023 Feb;77:31-38. doi: 10.1016/j.bjps.2022.11.009. Epub 2022 Nov 23.
引用本文的文献
1
Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy.对于接受新辅助芳香化酶抑制剂治疗的雌激素受体阳性乳腺癌患者，突变并非内分泌抵抗的常见机制。
Front Oncol. 2020 Apr 3;10:342. doi: 10.3389/fonc.2020.00342. eCollection 2020.
2
Constitutional mismatch repair-deficiency: current problems and emerging therapeutic strategies.先天性错配修复缺陷：当前问题与新兴治疗策略
Oncotarget. 2018 Oct 23;9(83):35458-35469. doi: 10.18632/oncotarget.26249.
本文引用的文献
1
CDK4/6 inhibition triggers anti-tumour immunity.细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制可触发抗肿瘤免疫。
Nature. 2017 Aug 24;548(7668):471-475. doi: 10.1038/nature23465. Epub 2017 Aug 16.
2
NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.NeoPalAna研究：新辅助哌柏西利（一种细胞周期蛋白依赖性激酶4/6抑制剂）联合阿那曲唑治疗临床2期或3期雌激素受体阳性乳腺癌
Clin Cancer Res. 2017 Aug 1;23(15):4055-4065. doi: 10.1158/1078-0432.CCR-16-3206. Epub 2017 Mar 7.
3
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).Ki67增殖指数作为新辅助芳香化酶抑制剂治疗乳腺癌期间及之后化疗决策工具：美国外科医师学会肿瘤学组Z1031试验（联盟）结果
J Clin Oncol. 2017 Apr 1;35(10):1061-1069. doi: 10.1200/JCO.2016.69.4406. Epub 2017 Jan 3.
4
Estrogen signaling and the DNA damage response in hormone dependent breast cancers.激素依赖性乳腺癌中的雌激素信号传导与DNA损伤反应
Front Oncol. 2014 May 14;4:106. doi: 10.3389/fonc.2014.00106. eCollection 2014.
Zotero 插件